Literature DB >> 19851747

[Pharmacological treatment of benign prostatic hyperplasia].

M Oelke1, M A Kuczyk, T R W Herrmann.   

Abstract

The majority of men with benign prostatic hyperplasia (BPH) seek medical help because of lower urinary tract symptoms (LUTS). Pharmacological treatment of BPH is indicated if the patient has no absolute indications for prostate surgery or benign prostatic obstruction (BPO), but LUTS with a decrease of quality of life. Plant extracts can be prescribed in men with mild to moderate symptoms. alpha-Blockers can quickly and effectively decrease LUTS and symptomatic disease progression. If patients have predominantly bladder filling symptoms and a small prostate, muscarinic receptor antagonists are a viable treatment option. The combination of an alpha-blocker plus a muscarinic receptor antagonist is more effective than single drugs used alone. Especially in men with larger prostates, 5alpha-reductase inhibitors can decrease LUTS and the probability of acute urinary retention as well as need for prostate surgery. The combination of alpha-blocker plus 5alpha-reductase inhibitor can reduce LUTS and disease progression more effectively than single drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851747     DOI: 10.1007/s00120-009-2141-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

Review 2.  [Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results].

Authors:  M Oelke; K Höfner; R R Berges; U Jonas
Journal:  Urologe A       Date:  2002-09       Impact factor: 0.639

3.  New words for old: lower urinary tract symptoms for "prostatism".

Authors:  P Abrams
Journal:  BMJ       Date:  1994-04-09

4.  Characteristics of patients presenting with LUTS/BPH in six European countries.

Authors:  Annie Hutchison; Richard Farmer; Christopher Chapple; Richard Berges; Ludger Pientka; Pierre Teillac; Andrzej Borkowski; Piotr Dobronski
Journal:  Eur Urol       Date:  2006-05-19       Impact factor: 20.096

5.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

6.  The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms.

Authors:  T J Peters; J L Donovan; H E Kay; P Abrams; J J de la Rosette; D Porru; J W Thüroff
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

Review 7.  [Treatment of LUTS in BPS. When and when not to administer pills?].

Authors:  R Berges
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

8.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

9.  Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.

Authors:  Matthias Oelke; Joyce Baard; Hessel Wijkstra; Jean J de la Rosette; Udo Jonas; Klaus Höfner
Journal:  Eur Urol       Date:  2008-02-25       Impact factor: 20.096

10.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

View more
  2 in total

1.  Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms : An overview.

Authors:  Rainer C Görne; Tankred Wegener; Olaf Kelber; Björn Feistel; Jürgen Reichling
Journal:  Wien Med Wochenschr       Date:  2016-11-29

2.  Inhibition of Human Prostate and Bladder Smooth Muscle Contraction, Vasoconstriction of Porcine Renal and Coronary Arteries, and Growth-Related Functions of Prostate Stromal Cells by Presumed Small Molecule Gαq/11 Inhibitor, YM-254890.

Authors:  Alexander Tamalunas; Amin Wendt; Florian Springer; Anna Ciotkowska; Beata Rutz; Ruixiao Wang; Ru Huang; Yuhan Liu; Heiko Schulz; Stephan Ledderose; Giuseppe Magistro; Christian G Stief; Martin Hennenberg
Journal:  Front Physiol       Date:  2022-05-23       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.